Accession Number : ADA192225

Title :   Ischemic-Anoxia of the Central Nervous System: Iron Dependent Oxidative Injury during Reperfusion.

Descriptive Note : Final rept. (Annual) 1 Sep 84-31 Aug 86; 1 Sep 85-31 Aug 86,

Corporate Author : MICHIGAN STATE UNIV EAST LANSING

Personal Author(s) : White, Blaine C ; Krause, Gary S ; Aust, Steven D ; Kumar, Kusum

PDF Url : ADA192225

Report Date : 15 Oct 1986

Pagination or Media Count : 39

Abstract : This work was begun with the recognition that the current practice of resuscitation from cardiac arrest due to either medical or traumatic causes results in major neurologic injury in 50-80% of resuscitated patients. Only in the last 25 years has there begun to be a systematic examination of the pathophysiology and molecular biology attendant to brain ischemia and reperfusion. The present work continues to examine the sequence of critical events in brain ischemia and reperfusion and tests therapies which may be applied during the reperfusion phase to inhibit the development of biochemical and functional markers of irreversible brain injury. The major products of this work are significant advances in the understanding of the pathophysiology of brain ischemia and reperfusion. During this period, flunarizine (calcium antagonist) and choloropromazine (effects in myocardium include inhibition of both phospholipase and of lipid peroxidation) for protective effects across the injury parameters were examined. Neither flunarizine nor chloropromazine have so far exhibited marked protective effects. Keywords: Dogs; Laboratory animals.

Descriptors :   *BRAIN, *CARDIAC ARREST, *ISCHEMIA, *ANOXIA, *RESUSCITATION, CALCIUM, CENTRAL NERVOUS SYSTEM, DOGS, INHIBITION, IRON, IRREVERSIBLE PROCESSES, LABORATORY ANIMALS, LIPIDS, MARKERS, MOLECULAR BIOLOGY, MYOCARDIUM, NERVOUS SYSTEM DISEASES, OXIDATION, PARAMETERS, PATHOPHYSIOLOGY, PROTECTION, SEQUENCES, WOUNDS AND INJURIES, PERFUSION, PHARMACOLOGICAL ANTAGONISTS, CHELATING AGENTS

Subject Categories : Medicine and Medical Research
      Biochemistry

Distribution Statement : APPROVED FOR PUBLIC RELEASE